Endostar
Also known as: Endostar injection, Recombinant Human Endostatin, rh-Endostatin, YH-16
Source Endostar at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Endostar is a recombinant human endostatin (amino‑terminal truncated) approved in China for treatment of non‑small cell lung cancer. It is administered by intravenous infusion and acts as a broad anti‑angiogenic agent.
Mechanism of Action
Inhibits endothelial cell proliferation, migration and tube formation; blocks VEGF/VEGFR signaling and induces endothelial apoptosis, thereby suppressing tumor angiogenesis.
Routes of Administration
Goals & Uses
- Nasopharyngeal carcinomaOncologyLow
- Non-small cell lung cancer (NSCLC) treatmentOncologyHigh
- Hepatocellular carcinomaOncologyModerate
- Tumor angiogenesis inhibitionOncology / AntiangiogenicHigh
- Non‑small cell lung cancerOncologyHigh
- Colorectal cancerOncologyModerate
- Malignant pleural effusionOncologyModerate
Contraindications
- Serious hypersensitivity to recombinant proteinsAllergy/ImmunologyHigh
- Severe hepatic impairmentOrganModerateLiver function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Severe cardiac dysfunctionCardiovascularHigh
Adverse Effects
- ProteinuriaRenalUncommon
- HypertensionCardiovascularCommonHigh blood pressure
- Nausea/vomitingGastrointestinalCommon
- NeutropeniaHematologicUncommonLow neutrophil count
- FatigueGeneralCommonLow energy or tiredness
- Cardiovascular events (arrhythmia, chest discomfort)CardiovascularUncommon
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- Infusion-related reactionsHypersensitivityUncommon
Drug Interactions
- Anticoagulants (e.g., warfarin)Moderate
- Vinorelbine/Cisplatin (NP regimen)Low
- Anticoagulants (warfarin, heparin)Moderate
- other anti‑angiogenic agents (e.g., bevacizumab)Moderate
Population Constraints
- Pediatric patientsAgeRelative
- Patients with hepatic impairmentOrgan FunctionRelative
- Elderly patients (>70 years)AgeRelative
- Lactating womenReproductiveAbsolute
- Elderly (>75 years)GeriatricRelative
Regulatory Status
- CNApprovedApproved: non‑small cell lung cancerApproved by NMPA (2015).
- European UnionUnapprovedNo EMA marketing authorization.
- United StatesUnapprovedInvestigational; not FDA‑approved.
- United KingdomUnapprovedNot approved by MHRA in the United Kingdom.
Approved by the National Medical Products Administration (NMPA, China) for NSCLC; not approved by FDA or EMA.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Endostar?
Endostar is a recombinant human endostatin (amino‑terminal truncated) approved in China for treatment of non‑small cell lung cancer. It is administered by intravenous infusion and acts as a broad anti‑angiogenic agent.
What is Endostar used for?
Endostar is educationally associated with: Nasopharyngeal carcinoma, Non-small cell lung cancer (NSCLC) treatment, Hepatocellular carcinoma, Tumor angiogenesis inhibition, Non‑small cell lung cancer, Colorectal cancer, Malignant pleural effusion. Educational only — not medical advice.
How is Endostar administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Endostar?
Reported adverse effects include: Proteinuria, Hypertension, Nausea/vomiting, Neutropenia, Fatigue, Cardiovascular events (arrhythmia, chest discomfort), Elevated liver enzymes, Infusion-related reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Endostar?
Recorded contraindications: Serious hypersensitivity to recombinant proteins, Severe hepatic impairment, Pregnancy, Severe cardiac dysfunction. Consult a qualified clinician before use.